Carbazochrome is an antihemorrhagic, or hemostatic, agent that will cease blood flow by causing the aggregation and adhesion of platelets in the blood to form a platelet plug, ceasing blood flow from an open wound. It is hoped that this drug can be used in the future for preventing excessive blood flow during surgical operations and the treatment of hemorrhoids, but research on its effectiveness and the severity of possible side effects remains to be fairly inconclusive.
Calcium binds to calmodulin which then binds and activates myosin light-chain kinase, that will enable the myosin crossbridge to bind to the actin filament and allow contraction to begin. This will change platelet’s shape and induce release of serotonin, ADP, vWF (Von Willebrand factor), PAF (Platelet-activating factor) to promote further aggregation and adhesion.
^Basile M, Gidaro S, Pacella M, Biffignandi PM, Gidaro GS (2001). "Parenteral troxerutin and carbazochrome combination in the treatment of post-hemorrhoidectomy status: a randomized, double-blind, placebo-controlled, phase IV study". Curr Med Res Opin17 (4): 256–61. doi:10.1185/030079901753403144. PMID11922398.
^Squadrito F, Altavilla D, Oliaro Bosso S (2000). "Double-blind, randomized clinical trial of troxerutin-carbazochrome in patients with hemorrhoids". Eur Rev Med Pharmacol Sci4 (1-2): 21–4. PMID11409185.